Epeius Biotechnologies is bringing genetic medicine to the patient with Rexin-G®, the world's first tumor-targeted delivery product.
Scientists at Epeius Biotechnologies have developed the world’s first targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, the first tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and superior single-agent efficacy in clinical trials internationally.
Rexin-G Rexin-G Rexin-G Rexin-G Rexin-G